Aclidinium bromide is a Small Molecule owned by Covis Group, and is involved in 2 clinical trials, which were completed. Aclidinium bromide is a competitive muscarinic receptor antagonist (also known as an anticholinergic), with subnanomolar affinity for all five human muscarinic receptor subtypes (M1-M5) and a longer residence time at the M3 receptors than the M2 receptors. M3 receptors mediate contraction of airway smooth muscle. Inhaled aclidinium bromide acts locally in the lungs to antagonise M3 receptors of airway smooth muscle and induce bronchodilation.
The revenue for Aclidinium bromide is expected to reach a total of $2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Aclidinium bromide NPV Report.
Aclidinium bromide Overview
Aclidinium bromide (Tudorza Pressair/Eklira Genuair/Tudorza Genuair/Bretaris Genuair )is a quinuclidines derivative acts as an anticholinergic agent. It is formulated as powder for inhalational route of administration. Aclidinium bromide is indicated for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis, bronchospasm and emphysema.
AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The COVID-19 Vaccine AstraZeneca has been approved for conditional marketing or emergency use. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.
The company reported revenues of (US Dollars) US$37,417 million for the fiscal year ended December 2021 (FY2021), an increase of 40.6% over FY2020. In FY2021, the company’s operating margin was 2.8%, compared to an operating margin of 19.4% in FY2020. In FY2021, the company recorded a net margin of 0.3%, compared to a net margin of 12% in FY2020. The company reported revenues of US$10,982 million for the third quarter ended September 2022, an increase of 2% over the previous quarter.
Quick View – Aclidinium bromide
|Highest Development Stage|